Abstract: A method for use in the treatment of diseases affecting the brain by providing exogenous Nav1.1 via CAV-2 vector-mediated delivery of a copy of SCNIA ORF into central nervous system (CNS) neurons. The method includes injection of the viral vector into the hippocampus and/or thalamus. Transcriptional control of the SCNIA expression cassette can be provided by specific promoters, such as NSE, to achieve targeted neuronal expression. This strategy is suitable as a therapeutic approach regardless of the underling SCNIA mutation. Moreover, because this approach compensates for the loss of function of Nav1.1, it can potentially ameliorate Dravet Syndrome, epileptic and non-epileptic comorbidities thereof, epilepsy, Alzheñner's, and other Nav1.1-associated pathological conditions.